Last updated: March 8, 2026
What is NDC 72888-0220?
NDC 72888-0220 refers to Nerlynx (neratinib), an oral tyrosine kinase inhibitor approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer. It was approved by the U.S. Food and Drug Administration (FDA) in July 2020. The drug is developed by Puma Biotechnology.
Market Size and Demand Drivers
Current Market Landscape
Nerlynx addresses a niche within the breast cancer therapeutics space, primarily targeting patients with early-stage HER2-positive disease following trastuzumab-based therapy.
- Estimated global breast cancer market value (2023): approximately US$20 billion.
- HER2-positive subset: about 15-20% of cases.
- Adjuvant therapy segment: represents roughly 25% of the total HER2+ breast cancer market, translating into an approximate US$750 million to US$1 billion market globally, with the U.S. accounting for over 50%.
Prescriptive Volume
- In 2022, estimates suggest 20,000 to 25,000 eligible patients annually in the U.S.
- Market penetration is limited but expected to grow as physicians adopt Nerlynx following results from clinical trials demonstrating extended disease-free survival.
Competitive Landscape
- Drugs targeting HER2+ breast cancer include trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla), and neratinib.
- Nerlynx's main competitors are other HER2-targeted agents used in different treatment settings, but it fills a specific niche for extended adjuvant therapy.
Pricing Analysis
Current Pricing Data
- As of 2023, the wholesale acquisition cost (WAC) for Nerlynx is approximately US$13,000 to US$15,000 per month.
- Treatment duration: generally 12 months, but can vary based on clinical response and tolerability.
Cost-Effectiveness
- The cost per treatment course: US$156,000 to US$180,000.
- Price points reflect factors such as manufacturing costs, patent status, and market positioning.
- Comparatively, Kadcyla averages around US$11,000 per month, but its treatment duration can differ.
Reimbursement and Insurance Coverage
- Reimbursement is generally in line with WAC, with high coverage in oncology centers.
- Patient out-of-pocket costs depend on insurance plans; co-pays can range from US$50 to US$200 per month.
Price Projections
Short-Term Outlook (2024-2026)
- Expect slight price stability unless new competitors or biosimilars emerge.
- Price erosion may occur due to increased market access negotiations, especially if biosimilars for competitor agents are approved.
Long-Term Outlook (2027 and beyond)
- Potential for a 10-15% reduction over five years, driven by increased competition and patent expiration.
- Accelerated approval processes for biosimilars or generic tyrosine kinase inhibitors could further pressure prices.
Influencing Factors
- Patent status: Patent expiry expected around 2030.
- Market penetration: Up to 10-15% of eligible patients may be prescribed Nerlynx initially, with potential growth as clinical adoption increases.
- Reimbursement policies: Shifts towards value-based pricing could influence net prices.
Key Considerations
- The drug’s niche status limits the impact of volume-based discounts.
- Pricing strategies will depend on payor acceptance and clinical guidelines updates.
- Biosimilar entry remains the primary long-term risk to price stability.
Key Takeaways
- NDC 72888-0220 (Nerlynx) has an estimated global adjuvant HER2-positive breast cancer market of US$750 million to US$1 billion.
- Current annual treatment costs are roughly US$156,000 to US$180,000 per patient.
- Short-term prices are stable, with slight declines expected from 2027 onward due to competition and patent progression.
- Market growth depends on increased clinical adoption and expanded indications, but pricing will be constrained by biosimilar and generic drug developments.
FAQs
1. When will Nerlynx face patent expiration, and how will that affect prices?
Patent protection is expected to expire around 2030. This may lead to biosimilar entries, potentially cutting prices by 30-50% depending on market adoption and regulatory approval.
2. Are there any approved biosimilars or generics for Nerlynx?
As of 2023, no biosimilars or generics for Nerlynx are approved. Biosimilars are generally not applicable due to the molecular complexity of tyrosine kinase inhibitors, but biosimilars for other HER2 therapies may influence the market.
3. How does Nerlynx compare economically to other HER2-targeted therapies?
Nerlynx costs approximately US$13,000–US$15,000 monthly, comparable to Kadcyla but with different treatment durations. Its value is primarily driven by efficacy data, with price remaining aligned to market norms for targeted oncology drugs.
4. What are the main factors influencing Nerlynx’s price stability?
Market penetration, clinical guidelines, reimbursement policies, and patent status are primary factors. Clinical trial outcomes influencing prescribing habits could also impact demand and pricing.
5. What is the likelihood of price reductions due to biosimilar competition?
While biosimilars are less likely to directly compete with Nerlynx due to its unique mechanism as a kinase inhibitor rather than a biologic, biosimilars for other HER2 drugs could influence overall market prices, especially in combination treatment paradigms.
Sources
- FDA. (2020). Neratinib (Nerlynx) approval. https://www.fda.gov
- IQVIA. (2023). Global Oncology Market Data.
- Bloomberg New Disease Market Insights. (2023). Oncology drug pricing.
- Puma Biotechnology. (2023). Nerlynx product information.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement data.
